LEO Pharma, a global leader in medical dermatology, has acquired Replay, a genome writing company, for $50.0 million. This transaction sees LEO Pharma take full ownership of Replay, which specializes in defining the future of genomic medicine through reprogramming biology by writing and delivering big DNA.
Replay has developed a comprehensive toolkit of disruptive platform technologies designed to overcome current limitations in genomic medicine. These include a high payload capacity HSV platform (synHSV™), a hypoimmunogenic platform, and a genome writing platform. The company's innovative hub-and-spoke business model separates core technology development within Replay from therapeutic applications in dedicated product companies. For instance, its synHSV™ technology, capable of delivering significantly larger genetic payloads than AAV, is leveraged by four gene therapy product companies targeting diseases of the skin, eye, brain, and muscle, alongside an enzyme writing product company utilizing evolutionary inference machine learning.
The acquisition is strategically significant for LEO Pharma, enabling the pharmaceutical company to integrate Replay's advanced genomic capabilities into its research and development pipeline. Replay's expertise in delivering large DNA payloads and its focus on developing treatments for skin diseases align directly with LEO Pharma's established leadership in dermatology. This move is expected to accelerate LEO Pharma's pursuit of novel, potentially curative, genomic therapies for complex dermatological conditions and other unmet medical needs.
By bringing Replay's innovative platforms and scientific talent under its umbrella, LEO Pharma aims to unlock new therapeutic avenues and enhance its position in advanced medicine. The combined entity is poised to leverage Replay's foundational genomic technologies with LEO Pharma's extensive pharmaceutical development and commercialization infrastructure, fostering the creation of next-generation treatments and expanding the reach of genomic medicine.